- Home
- NRT vs CELU Comparison
NRT vs CELU Comparison
Compare NRT & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRT
- CELU
- Stock Information
- Founded
- NRT 1975
- CELU 2016
- Country
- NRT United States
- CELU United States
- Employees
- NRT N/A
- CELU N/A
- Industry
- NRT Oil & Gas Production
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- NRT Energy
- CELU Health Care
- Exchange
- NRT Nasdaq
- CELU Nasdaq
- Market Cap
- NRT 46.4M
- CELU 42.2M
- IPO Year
- NRT N/A
- CELU N/A
- Fundamental
- Price
- NRT $5.00
- CELU $3.71
- Analyst Decision
- NRT
- CELU Buy
- Analyst Count
- NRT 0
- CELU 1
- Target Price
- NRT N/A
- CELU $6.00
- AVG Volume (30 Days)
- NRT 41.1K
- CELU 91.6K
- Earning Date
- NRT 08-29-2025
- CELU 10-15-2025
- Dividend Yield
- NRT 9.66%
- CELU N/A
- EPS Growth
- NRT 24.05
- CELU N/A
- EPS
- NRT 0.59
- CELU N/A
- Revenue
- NRT $6,184,173.00
- CELU $54,220,000.00
- Revenue This Year
- NRT N/A
- CELU $23.29
- Revenue Next Year
- NRT N/A
- CELU N/A
- P/E Ratio
- NRT $8.63
- CELU N/A
- Revenue Growth
- NRT 18.55
- CELU 138.11
- 52 Week Low
- NRT $3.88
- CELU $1.00
- 52 Week High
- NRT $5.92
- CELU $5.22
- Technical
- Relative Strength Index (RSI)
- NRT 44.33
- CELU 68.77
- Support Level
- NRT $5.36
- CELU $3.03
- Resistance Level
- NRT $5.75
- CELU $4.31
- Average True Range (ATR)
- NRT 0.21
- CELU 0.27
- MACD
- NRT -0.03
- CELU 0.05
- Stochastic Oscillator
- NRT 30.30
- CELU 80.60
About NRT North European Oil Royality Trust
North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.